All eligible to vote Principal Investigators (672) from EBMT full membership centres were invited to vote online for the nominated, endorsed and approved Working Party Chair candidates for 2026, in addition to approving the activity reports (President, Secretary and Treasurer) and bylaws amendments. 299 of 672 ballots were cast.
Voting took place online from Tuesday 10 March 2026. The elections results were announced live at the General Assembly Meeting on Tuesday 24 March, during the 52nd Annual Meeting of the EBMT.
You will find the results of this online election below:
EBMT Working Party Chairs
Acute Leukaemia Working Party
| 271 votes tallied and 28 abstentions | Votes | Percentage |
|---|---|---|
| Eolia Brissot | 271 | 100.00% |
Eolia Brissot
Paris, France
Chronic Malignancies Working Party
| 290 votes tallied and 9 abstentions | Votes | Percentage |
|---|---|---|
| Nicola Polverelli | 52 | 17.93% |
| Carmelo Gurnari | 52 | 17.93% |
| Christof Scheid | 63 | 21.72% |
| Marie Robin | 93 | 32.07% |
| Joanna Drozd-Sokolawska | 30 | 10.34% |
Marie Robin
Paris, France
I am very happy and honoured to have been elected Chair of the EBMT Chronic Malignancies Working Party to serve all members around scientific issues related to this working party. One of my challenges would be to improve information regarding molecular alterations by being closer to centres, with optimisation for data collection and collaborations with extra-EBMT groups, so as to improve the quality of the studies.
Our group can count on plenty of motivated people that would work together to produce high-quality work to serve patients and optimise their care.
Cellular Therapy and Immunobiology Working Party
| 273 votes tallied and 26 abstentions | Votes | Percentage |
|---|---|---|
| Jürgen Kuball | 143 | 52.38% |
| Florent Malard | 130 | 47.62% |
Jürgen Kuball
Utrecht, The Netherlands
I have seen how evidence generated by our community shapes innovation and access through my work bridging immune biology, clinical practice, and regulation, including leadership roles within EBMT. This perspective is essential for the CTIWP’s next phase. As cellular immunotherapies enter a period where scientific progress, regulatory requirements, and access are increasingly intertwined, the CTIWP must actively address this intersection. As Chair, I will focus on empowering investigator-led projects, strengthening collaboration across Working Parties, and ensuring that high-quality science translates into equitable patient access. If we do not actively define this space, others will.
JACIE Working Party
| 259 votes tallied and 40 abstentions | Votes | Percentage |
|---|---|---|
| Charles Crawley | 259 | 100.00% |
Charles Crawley
Cambridge, The United Kingdom
EBMT 2025 Annual Activity Reports Approval
In addition to voting online for the nominated candidates, PIs were also asked to approve the President's, Secretary's and the Treasurer's reports and the Bylaw Amendments Approval in advance of the Annual General Assembly Meeting 2026.
EBMT President's Activity Report 2025
| Yes - I approve the President's Activity Report 2025 | 274 votes (98.92%) |
|---|---|
| No - I reject the President's Activity Report 2025 | 3 votes (1.08%) |
| 277 votes tallied and 22 abstentions |
EBMT Treasurer's Annual Report for 2025
| Yes - I approve the Treasurer's Annual Report for 2025 | 260 votes (97.38%) |
|---|---|
| No - I reject the Treasurer's Annual Report for 2025 | 7 votes (2.62%) |
| 267 votes tallied and 32 abstentions |
EBMT Secretary's Annual Report for 2025
| Yes - I approve the Secretary's Annual Report for 2025 | 275 votes (99.28%) |
|---|---|
| No - I reject the Secretary's Annual Report for 2025 | 2 votes (0.72%) |
| 277 votes tallied and 22 abstentions |
EBMT 2026 Bylaw Amendments Approval
| Yes - I approve the 2026 Bylaw Amendments Package | 139 votes (93.29%) |
|---|---|
| No - I reject the 2026 Bylaw Amendments Package | 10 votes (6.71%) |
| 149 votes tallied and 11 abstentions |
2026 Committee Chair Appointments
Following validation and Board approval, the following appointments have been confirmed:
Fabio Ciceri – Registry Committee Chair
Arnon Nagler – Global Committee Chair
Donal McLornan – Practice Harmonisation & Guidelines Chair
Dimitris Protogiros – Equality, Diversity & Inclusion Committee Chair
Andrea Linke & Jacqueline del Castillo – Patient & Advocacy Committee Co-Chairs
Rick Admiraal – Pharmacist Committee Chair
All chairs will assume their roles immediately after the conclusion of the Annual Meeting 2026 in Madrid, ensuring a smooth leadership transition.
Outgoing Board Members
We would like to thank the following outgoing Board Members for their support and commitment to the Scientific Council and Board of Association during their mandates:
Annalisa Ruggeri - EBMT Cellular Therapy & Immunobiology Working Party Chair (2022–2026) and Scientific Council Representative with the Educational Portfolio (2024–2026)
Donal McLornan - EBMT Chronic Malignancies Working Party Chair (2022–2026) and Scientific Council Co-Chair with the Research and Sciences Portfolio (2023–2026)
Fabio Ciceri - EBMT Acute Leukaemia Working Party Chair (2022–2026) and Scientific Council Chair with the Research and Sciences Portfolio (2023–2026)
Michelle Kenyon - EBMT Nurses Group President (2019–2025) and Member of the Board of Association (2019–2026)
Anna Sureda Balari - EBMT President, Member of the Executive Committee, and Board of Association (2022–2026)